Identifying cancer origin using circulating tumor cells

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87-108; PMID:25651787; http://dx.doi.org/10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011; 192:373-82; PMID:21300848; http://dx.doi.org/10.1083/jcb.201010021
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6:339-51; PMID:19399023; http://dx.doi.org/10.1038/nrclinonc.2009.44
   PubMed Web of Science ®Google Scholar
• Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther 2014; 141:209-21; PMID:24134902; http://dx.doi.org/10.1016/j.pharmthera.2013.10.004
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-91; PMID:15317891; http://dx.doi.org/10.1056/NEJMoa040766
   PubMed Web of Science ®Google Scholar
• Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40:403-39; PMID:12010363; http://dx.doi.org/10.1046/j.1365-2559.2002.01387.x
   PubMed Web of Science ®Google Scholar
• Arrieta O, Pineda B, Muniz-Hernandez S, Flores D, Ordonez G, Borbolla-Escoboza JR, Orta D. Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients. Cancer Biomarkers 2014; 14:215-23; PMID:24934364; http://dx.doi.org/10.3233/CBM-140394
   PubMed Web of Science ®Google Scholar
• Knosel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I. Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol 2006; 28:167-75; PMID:16988472; http://dx.doi.org/10.1155/2006/354295
   PubMed Web of Science ®Google Scholar
• Castillo V, Valenzuela R, Huidobro C, Contreras HR, Castellon EA. Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol 2014; 45:985-94; PMID:24990514
   PubMed Web of Science ®Google Scholar
• Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmuller G, Pantel K. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 1993; 99:61-6; PMID:7682210; http://dx.doi.org/10.1007/BF00268022; http://dx.doi.org/10.3892/ijo.2014.2529
   PubMedGoogle Scholar
• Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clinical Chem 2007; 53:1206-15; PMID:17525108; http://dx.doi.org/10.1373/clinchem.2006.081828
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one 2012; 7:e35976; PMID:22558290; http://dx.doi.org/10.1371/journal.pone.0035976
   PubMed Web of Science ®Google Scholar
• Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Science translational medicine 2010; 2:25ra3; PMID:20424012; http://dx.doi.org/10.1126/scitranslmed.3000403
   Web of Science ®Google Scholar
• Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts'o PO. Identification and characterization of circulating prostate carcinoma cells. Cancer 2000; 88:2787-95; PMID:10870062; http://dx.doi.org/10.1002/1097-0142(20000615)88:12%3c2787::AID-CNCR18%3e3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Welinder C, Jansson B, Lindell G, Wenner J. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. Cancer letters 2015; 358:43-6; PMID:25528628; http://dx.doi.org/10.1016/j.canlet.2014.12.024
   PubMed Web of Science ®Google Scholar
• Wong SC, Ng SS, Cheung MT, Luk LY, Chan CM, Cheung AH, Lee VH, Lai PB, Ma BB, Hui EP, et al. Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. Br J Cancer 2011; 104:1000-6; PMID:21364588; http://dx.doi.org/10.1038/bjc.2011.32
   PubMed Web of Science ®Google Scholar
• Chang YL, Lee YC, Liao WY, Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004; 44:149-57; PMID:15084379; http://dx.doi.org/10.1016/j.lungcan.2003.10.008
   PubMed Web of Science ®Google Scholar
• Casavant BP, Strotman LN, Tokar JJ, Thiede SM, Traynor AM, Ferguson JS, Lang JM, Beebe DJ. Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. Lab on a chip 2014; 14:99-105; PMID:24158597; http://dx.doi.org/10.1039/C3LC50912E
   PubMed Web of Science ®Google Scholar
• Lai JM, Shao HJ, Wu JC, Lu SH, Chang YC. Efficient elusion of viable adhesive cells from a microfluidic system by air foam. Biomicrofluidics 2014; 8:052001; PMID:25332725; http://dx.doi.org/10.1063/1.4893348
   PubMedGoogle Scholar
• Wu JC, Tseng PY, Tsai WS, Liao MY, Lu SH, Frank CW, Chen JS, Wu HC, Chang YC. Antibody conjugated supported lipid bilayer for capturing and purification of viable tumor cells in blood for subsequent cell culture. Biomaterials 2013; 34:5191-9; PMID:23615560; http://dx.doi.org/10.1016/j.biomaterials.2013.03.096
   PubMed Web of Science ®Google Scholar
• Chan CW, Wong NA, Liu Y, Bicknell D, Turley H, Hollins L, Miller CJ, Wilding JL, Bodmer WF. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci U S A 2009; 106:1936-41; PMID:19188603; http://dx.doi.org/10.1073/pnas.0812904106
   PubMed Web of Science ®Google Scholar
• Abe M, Havre PA, Urasaki Y, Ohnuma K, Morimoto C, Dang LH, Dang NH. Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines. BMC cancer 2011; 11:51; PMID:21284881; http://dx.doi.org/10.1186/1471-2407-11-51
   PubMed Web of Science ®Google Scholar
• Jiang J, Ulbright TM, Younger C, Sanchez K, Bostwick DG, Koch MO, Eble JN, Cheng L. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med 2001; 125:921-3; PMID:11419977; http://dx.doi.org/10.0003-9985(2/0003-9985(2001)125<0921:CACIPU>2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 2002; 38:758-63; PMID:11937308; http://dx.doi.org/10.1016/S0959-8049(02)00008-4
   PubMed Web of Science ®Google Scholar
• Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014; 2:273-85; PMID:25606573
   PubMedGoogle Scholar
• Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158:1110-22; PMID:25171411; http://dx.doi.org/10.1016/j.cell.2014.07.013
   PubMed Web of Science ®Google Scholar
• Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30:525-32; PMID:22253462; http://dx.doi.org/10.1200/JCO.2010.33.3716
   PubMed Web of Science ®Google Scholar
• Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, Lee KY. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 2010; 40:208-13; PMID:19926591; http://dx.doi.org/10.1093/jjco/hyp150
   PubMed Web of Science ®Google Scholar
• Takami H, Sentani K, Matsuda M, Oue N, Sakamoto N, Yasui W. Cytokeratin expression profiling in gastric carcinoma: clinicopathologic significance and comparison with tumor-associated molecules. Pathobiology 2012; 79:154-61; PMID:22286119; http://dx.doi.org/10.1159/000335694
   PubMed Web of Science ®Google Scholar
• Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17:1392-9; PMID:15205684; http://dx.doi.org/10.1038/modpathol.3800205
   PubMed Web of Science ®Google Scholar
• Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, Askin F, Gabrielson E, Li QK. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clin Translational Med 2015; 4:16; PMID:25977750; http://dx.doi.org/10.1186/s40169-015-0057-2
   PubMedGoogle Scholar
• Tot T. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases. Ann Diagn Pathol 1999; 3:350-6; PMID:10594286; http://dx.doi.org/10.1016/S1092-9134(99)80013-6
   PubMedGoogle Scholar
• Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131:1561-7; PMID:17922593; http://dx.doi.org/ 10.1043/1543-2165(2007)131[1561:POIMHD]2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Dettmer M, Kim TE, Jung CK, Jung ES, Lee KY, Kang CS. Thyroid transcription factor-1 expression in colorectal adenocarcinomas. Pathol Res Pract 2011; 207:686-90; PMID:22019009; http://dx.doi.org/10.1016/j.prp.2011.08.009
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82:2256-61; PMID:9610707; http://dx.doi.org/10.1002/(SICI)1097-0142(19980601)82:11%3c2256::AID-CNCR22%3e3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52:637-40; PMID:9763084; http://dx.doi.org/10.1016/S0090-4295(98)00278-7
   PubMed Web of Science ®Google Scholar
• Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011; 71:281-8; PMID:20809553; http://dx.doi.org/10.1002/pros.21241
   PubMed Web of Science ®Google Scholar
• Bernacki KD, Fields KL, Roh MH. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma. Diagn Cytopathol 2014; 42:570-5; PMID:24273068; http://dx.doi.org/10.1002/dc.23075
   PubMed Web of Science ®Google Scholar
• Kraus TS, Cohen C, Siddiqui MT. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol 2010; 5:63; PMID:20863373; http://dx.doi.org/10.1186/1746-1596-5-63
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Jr., Wang CY, Haas GP. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30:628-36; PMID:16555021; http://dx.doi.org/10.1007/s00268-005-0544-5
   PubMed Web of Science ®Google Scholar
• Babayan A, Hannemann J, Spotter J, Muller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 2013; 8:e75038; PMID:24058649; http://dx.doi.org/10.1371/journal.pone.0075038
   PubMed Web of Science ®Google Scholar
• Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, et al. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther 2015; 14:2401-8; PMID:26227487; http://dx.doi.org/10.1158/1535-7163.MCT-15-0359
   PubMed Web of Science ®Google Scholar
• Lin HC, Hsu HC, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng CP. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta 2013; 419:77-84; PMID:23415697; http://dx.doi.org/10.1016/j.cca.2013.01.018
   PubMed Web of Science ®Google Scholar
• Nel I, Jehn U, Gauler T, Hoffmann AC. Individual profiling of circulating tumor cell composition in patients with non-small cell lung cancer receiving platinum based treatment. Transl Lung Cancer Res 2014; 3:100-6; PMID:25806288; http://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.05
   PubMedGoogle Scholar
• DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000; 17:184-93; PMID:10968704
   PubMed Web of Science ®Google Scholar
• Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72; PMID:15897574; http://dx.doi.org/10.1158/1078-0432.CCR-04-2236
   PubMed Web of Science ®Google Scholar